SCO­TUS de­clines to re­view En­brel biosim­i­lar case, tee­ing up 30+ years of ex­clu­siv­i­ty and $20B more for Am­gen’s block­buster

As the House Over­sight Com­mit­tee is set to grill Ab­b­Vie CEO Richard Gon­za­lez on Tues­day over tac­tics to block com­pe­ti­tion for its best-sell­ing drug of all time, an­oth­er de­ci­sion on Capi­tol Hill on Mon­day opened the door for bil­lions more in Am­gen prof­its over the next eight years.

The Supreme Court on Mon­day de­nied No­var­tis sub­sidiary San­doz’s pe­ti­tion to re­view a Fed­er­al Cir­cuit’s Ju­ly 2020 de­ci­sion con­cern­ing its biosim­i­lar Erelzi (etan­er­cept-sz­zs), which FDA ap­proved in 2016 as a biosim­i­lar to Am­gen’s En­brel (etan­er­cept). Sam­sung’s En­brel biosim­i­lar Eti­co­vo al­so won ap­proval in 2019 and re­mains side­lined.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER